Entrada Therapeutics annual return on equity
2021
2022
2023
2024
2025
Entrada Therapeutics Return on Equity (ROE) Growth & History (TRDA)
Entrada Therapeutics's return on equity was −39.13% for fiscal 2025.
View full Entrada Therapeutics company overviewEntrada Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −39.13% | −58.69 pp |
| 2024 | 2024-12-31 | 19.56% | +22.50 pp |
| 2023 | 2023-12-31 | −2.94% | +34.07 pp |
| 2022 | 2022-12-31 | −37.01% | +2.76 pp |
| 2021 | 2021-12-31 | −39.78% | — |
Entrada Therapeutics quarterly return on equity
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −16.96% | −6.14 pp |
| Q1 2026 | 2026-03-31 | −13.77% | −9.67 pp |
| Q4 2025 | 2025-12-31 | −12.11% | −12.37 pp |
| Q3 2025 | 2025-09-30 | −12.26% | −8.96 pp |
| Q2 2025 | 2025-06-30 | −10.82% | −26.56 pp |
| Q1 2025 | 2025-03-31 | −4.10% | −13.28 pp |
| Q4 2024 | 2024-12-31 | 0.27% | +4.17 pp |
| Q3 2024 | 2024-09-30 | −3.29% | −18.93 pp |
| Q2 2024 | 2024-06-30 | 15.74% | +27.62 pp |
| Q1 2024 | 2024-03-31 | 9.18% | +12.20 pp |
| Q4 2023 | 2023-12-31 | −3.90% | +7.15 pp |
| Q3 2023 | 2023-09-30 | 15.64% | +25.91 pp |
| Q2 2023 | 2023-06-30 | −11.88% | −3.19 pp |
| Q1 2023 | 2023-03-31 | −3.02% | +4.50 pp |
| Q4 2022 | 2022-12-31 | −11.05% | +5.27 pp |
| Q3 2022 | 2022-09-30 | −10.28% | — |
| Q2 2022 | 2022-06-30 | −8.69% | — |
| Q1 2022 | 2022-03-31 | −7.52% | — |
| Q4 2021 | 2021-12-31 | −16.32% | — |
Entrada Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Entrada Therapeutics's return on equity increased from −39.78% to −39.13%, a change of +0.65 percentage points. The latest reported quarter, Q2 2026, shows −16.96%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Entrada Therapeutics source filings ↗